Table 5.

In vitro cytotoxicity of (Z) and (E)-styryl benzyl sulfides, sulfoxides and sulfones

Compd	Structure	Isomer	K562b IC50a (μ M)	DU145c IC50a (μ M)
11		Z	15 ± 0.9	35 ± 2.1
12		E	5 ± 0.2	5 ± 0.2.8
13		Z	75 ± 5.0	>100
14		E	15 ± 0.7	17 ± 0.6
15		Z	15 ± 0.6	15 ± 0.75
16		E	2.5 ± 0.15	2.5 ± 0.1
17		Z	0.25 ± 0.01	0.75 ± 0.04
18		E	0.03 ± 0.002	0.05 ± 0.003
19		Z	5 ± 0.3	5 ± 0.2
20		E	0.02 ± 0.0015	0.04 ± 0.002
21		Z	0.15 ± 0.006	0.15 ± 0.005
22		E	0.003 ± 0.0002	0.003 ± 0.0001
23		Z	40 ± 2.0	38 ± 2.2
24		E	0.1 ± 0.004	0.1 ± 0.002
25		Z	37 ± 1.5	35 ± 2.0
26		E	0.0075 ± 0.0003	0.08 ± 0.004

^aIC₅₀: represents the compound concentration (μM) that is lethal to survival of 50% of tumor cells following 96 h treatment with the tested compound; values represent the average ± SD of two experiments.

^bK562: myelogenous leukemia.

^cDU145: human prostate cancer.